Leukemia drug trial halted early after company decision
NCT ID NCT05155709
Summary
This study tested whether adding an experimental drug called siremadlin to two standard leukemia drugs could improve treatment responses for adults with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. It aimed to find a safe dose and see if the three-drug combination could help patients who didn't respond well to initial treatment or those with high-risk newly diagnosed disease. The trial was stopped early by the drug company after enrolling 14 patients, not due to safety concerns, so no final results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Budapest, H-1083, Hungary
-
Novartis Investigative Site
Beersheba, 8457108, Israel
-
Novartis Investigative Site
Jerusalem, 9112001, Israel
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Alor Star, Kedah, 05460, Malaysia
-
Novartis Investigative Site
Kuala Selangor, 68000, Malaysia
-
Novartis Investigative Site
Izmir, 35340, Turkey (Türkiye)
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Texas Oncology Sammons Cancer Center
Dallas, Texas, 78246, United States
Conditions
Explore the condition pages connected to this study.